| PMC full text: | Published online 2022 Sep 1. doi: 10.1001/jamaoncol.2022.3829
|
Table 1.
Multivariable Analysis of Prognostic Factors for Overall Survival Present at Study Inclusion
| Factor | HR (95% CI)a | P valueb |
|---|---|---|
| Adjuvant chemotherapy | ||
| Gemcitabine | 1 [Reference] | <.001 |
| mFOLFIRINOX | 0.65 (0.51-0.82) | |
| Center volume | ||
| Inclusion of ≥10 patients | 0.77 (0.61-0.98) | .03 |
| Inclusion of <10 patients | 1 [Reference] | |
| Age, y | ||
| <70 | 0.70 (0.52-0.93) | .02 |
| ≥70 | 1 [Reference] | |
| Tumor grading | ||
| Well differentiated | 0.69 (0.53-0.90) | .01 |
| Moderately/poorly/undifferentiated | 1 [Reference] | |
| Tumor staging | ||
| IA/IB | 0.10 (0.03-0.33) | .002 |
| IIA | 0.24 (0.09-0.60) | |
| IIB | 0.35 (0.17-0.72) | |
| III/IV | 1 [Reference] |
Abbreviations: HR, hazard ratio; mFOLFIRINOX, modified fluorouracil, leucovorin, irinotecan, and oxaliplatin.
a
Stratified Cox model and log-rank test on lymph node status, resection margins, and postoperative CA 19-9.
b
Likelihood ratio test.